Best in Biotech 4 Apr 2024
Regenerative medicine and tissue engineering: Six companies leading the way
Discover six innovative companies leading the way in the evolving landscape of the tissue engineering and regenerative medicine industry.
Skin disease
- Latest Posts
In Depth 8 Feb 2024
Could we see a new dawn for hair loss treatments?
Discover the latest advances in hair loss treatments, from topical therapies to the the groundbreaking potential of JAK inhibitors.
Podcast 5 Jan 2024
Gene editing in the microbiome could provide acne solution
Explore Eligo Bioscience’s groundbreaking CRISPR-based approach, modifying the microbiome to combat moderate to severe acne.
Best in Biotech 23 Aug 2023
Latest advancements in psoriasis research over the past year
Psoriasis, an autoimmune condition that causes flaky patches of skin to form scales, occurs when the body’s immune system attacks its own healthy skin cells. And because people with psoriasis have an increased production of skin cells, these cells – which are normally renewed every three to four weeks – regenerate in under a week. […]
News and Trends 23 Jun 2023
Breakthrough treatment for skin infections?
A research team led by Kelvin Yeung from the Department of Orthopaedics and Traumatology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has designed a new microneedle patch that provides an effective non-antibiotic approach for the treatment of skin infections. The design engineered with ultrasound-responsive zinc-based metal-organic framework (MOF) […]
News and Trends 23 Mar 2023
Intracellular “smoke detector” discovery has skin disease therapy implications
A study by the University of Bonn in Germany could lead to therapies against skin and intestinal diseases in the medium term.Researchers at the universities of Bonn and Singapore have discovered a new intracellular “smoke detector.” The sensor warns of damage to the mitochondria – the microscopic power plants that supply the cell with energy. […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 3 Mar 2023
Let’s Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to Treat
While we mostly think of disease as being caused by bacteria or viruses, an illness can often occur when the body’s own defenses turn against itself. Here we’ll take a look at seven rare autoimmune diseases you may not have heard of and what biotechs are doing to treat them. The body’s immune system can […]
News and Trends 27 Jan 2023
Dupixent gets EU nod for children with severe atopic dermatitis
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent (dupilumab), recommending expanded approval in the European Union (EU) to treat severe atopic dermatitis in children six months to five years old who are candidates for systemic therapy. The European Commission is expected to announce a final […]
News and Trends 4 Jan 2023
Aditxt forms Adimune to focus on immune modulation therapies
Aditxt, Inc., a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has formed a U.S.-based subsidiary Adimune, Inc. The plan is to submit a clinical trial application (CTA) for its immunotherapeutic technology drug candidate, ADI-100 (ADI). The CTA will request approval for Adimune to conduct the […]
News and Trends 15 Dec 2022
European Commission approves Dupixent as first and only targeted prurigo nodularis medicine
The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials […]
News and Trends 30 Nov 2022
TrialSpark acquires immunodermatology portfolio and creates Libertas Bio
TrialSpark has announced the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences. The Libertas Bio pipeline now includes global rights to gusacitinib, an oral phase 3-ready dual JAK/SYK inhibitor in development for chronic hand eczema (CHE), and ASN008, a phase 2-ready topical sodium […]
News and Trends 21 Nov 2022
New Replay HSV gene therapy company Telaria to focus on skin diseases
Replay has announced the launch of Telaria, a herpes simplex virus (HSV) gene therapy company targeting rare skin diseases. It is the second of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Telaria’s co-founders are HSV scientists, entrepreneurs, and specialists in genetic skin diseases. In addition to Joe Glorioso, Telaria’s […]
ADVERTISEMENT